# Anti-Migraine Agents, Prophylaxis

This is a subcategory of Central Nervous System (CNS) Agents.

## Length of Authorizations

Initial Authorization 180 days

 Subsequent Authorizations 365 days

## Prior Authorization Criteria

- Is there any reason the patient cannot be changed to a medication not requiring prior approval?

    Acceptable reasons include:

  - Allergy to preferred medications
  - Contraindication to **three** preferred medications
  - History of unacceptable/toxic side effects/intolerance to at least **three** preferred medications

## Additional Criteria

### Step Therapy

Step Therapy Required Preferred Medications

- For a drug requiring step therapy, there must have been inadequate clinical response to a trial of at least 30 days each to at least 3 controller migraine medications or has experienced contraindications or intolerance to them (i.e., beta-blockers, anticonvulsants, tricyclic antidepressants, and/or serotonin-norepinephrine reuptake inhibitors).

### Non-Preferred Medication

- For a non-preferred medication drug there must have been inadequate clinical response to a trial of at least 30 days each to at least 3 controller migraine medications or has experienced contraindications or intolerance to them (i.e., beta-blockers, anticonvulsants, tricyclic antidepressants, and/or serotonin-norepinephrine reuptake inhibitors) AND an inadequate clinical response or intolerance to a trial of at least 30 days of one step therapy required preferred medication

### Migraine Prophylaxis

Additional Criteria for Migraine Prophylaxis

1. Patient must have one of the following diagnoses:

   - **Episodic** migraine with the following frequencies of migraine:
      - 4-15 headaches per 30 days measured over 90 consecutive days and headache duration of longer than 4 hours per day or longer during an attack on average.

    - **Chronic** migraine with the following frequencies of migraine:
        - 15 or more headaches per 30 days measured over 90 consecutive days and headache duration of longer than 4 hours per day or longer during an attack on average

2. Prior Authorization may be approved if the patient has failed a trial of at least 30 days each to at least 3 controller migraine medications or has experienced contraindications or intolerance to them (i.e., beta-blockers, anticonvulsants, tricyclic antidepressants, and/or serotonin-norepinephrine reuptake inhibitors).
3. Initial authorization will be limited to 180 days. Re-authorization for 365 days will be allowed based upon evidence of improved headache control (such as headache diary or attestation of ongoing efficacy from provider).

\*Aimovig Initial Dose is limited to 70mg once per 30 days; may request dose increase if 70mg fails to provide adequate relief over 60 consecutive days.

\* Ajovy 675mg doses (quarterly administration) will not be authorized until patient has demonstrated efficacy of medication for at least 90 days.

## Formulary

Central Nervous System (CNS) Agents: Anti-Migraine Agents, Prophylaxis

### Preferred

| Preferred                                                |
| :------------------------------------------------------- |
| Aimovig QL ST                                            |
| Ajovy ST                                                 |
| Cardiovascular Agents: Beta-Blockers                     |
| CNS Agents: Anticonvulsants                              |
| CNS Agents: Serotonin-Norepinephrine Reuptake Inhibitors |
| CNS Agents: Tricyclic Antidepressants                    |

### Non-Preferred

| Non-Preferred |
| :------------ |
| Emgality      |
| Nurtec ODT    |
| Qulipta       |

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=25)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=13)